Globus Medical (NYSE:GMED – Get Free Report) and Beauty Health (NASDAQ:SKIN – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.
Institutional and Insider Ownership
95.2% of Globus Medical shares are owned by institutional investors. Comparatively, 93.3% of Beauty Health shares are owned by institutional investors. 18.5% of Globus Medical shares are owned by company insiders. Comparatively, 41.0% of Beauty Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Globus Medical and Beauty Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Globus Medical | 3.69% | 9.98% | 7.92% |
| Beauty Health | -8.11% | -44.83% | -3.54% |
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Globus Medical | $2.48 billion | 4.74 | $122.87 million | $0.67 | 128.87 |
| Beauty Health | $347.62 million | 0.63 | -$100.12 million | ($0.42) | -4.21 |
Globus Medical has higher revenue and earnings than Beauty Health. Beauty Health is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings for Globus Medical and Beauty Health, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Globus Medical | 1 | 2 | 9 | 0 | 2.67 |
| Beauty Health | 1 | 3 | 1 | 0 | 2.00 |
Globus Medical presently has a consensus target price of $94.55, suggesting a potential upside of 9.50%. Beauty Health has a consensus target price of $2.55, suggesting a potential upside of 44.07%. Given Beauty Health’s higher possible upside, analysts clearly believe Beauty Health is more favorable than Globus Medical.
Volatility and Risk
Globus Medical has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Beauty Health has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500.
Summary
Globus Medical beats Beauty Health on 12 of the 14 factors compared between the two stocks.
About Globus Medical
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
About Beauty Health
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.
